Home
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Clinical trial condition

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Explore clinical trials studying Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Study availability and eligibility vary by location and protocol.

607 public trials 71 recruiting studies

Refine in advanced search Browse all conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive trial results

Completed

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

NCT01254188

Conditions: Bone Marrow Diseases, Chromosome Aberrations, Chronic Disease, +14 more
Locations: Novartis Investigative Site Algiers, Bouzareah, Algeria

Novartis Investigative Site Oran, Algeria

Novartis Investigative Site Buenos Aires, Argentina

Novartis Investigative Site Caba, Buenos Aires, Argentina

View all 100 locations

View Trial Details

Completed

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

NCT01413568

Conditions: Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Blood Protein Disorders, +36 more
Locations: University of Kansas Cancer Center Kansas City, Kansas, United States

Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Completed

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

NCT00975975

Conditions: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Anemia, +47 more
Locations: Indiana University Cancer Center Indianapolis, Indiana, United States

View Trial Details

Completed

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

NCT01511289

Conditions: Bone Marrow Diseases, Chromosome Aberrations, Chronic Disease, +14 more
Locations: Local Institution Jakarta, Indonesia

Local Institution Batangas, Philippines

Local Institution Manila, Philippines

Local Institution Busan, South Korea

View all 22 locations

View Trial Details

Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

NCT00002766

Conditions: Blast Crisis, Bone Marrow Diseases, Carcinogenesis, +21 more
Locations: Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States

Stanford Cancer Center at Stanford University Medical Center Stanford, California, United States

Winship Cancer Institute of Emory University Atlanta, Georgia, United States

Memorial Sloan-Kettering Cancer Center New York, United States

View Trial Details

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

NCT01227577

Conditions: Bone Marrow Diseases, Chronic Disease, Chronic Myelogenous Leukemia in Chronic Phase, +11 more
Locations: Pacific Cancer Medical Center, Inc. Anaheim, California, United States

Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer Burbank, California, United States

Bay Area Cancer Research Dept.ofBayAreaCancerResearch Concord, California, United States

St. Jude Heritage Medical Group Virginia Crosson Cancer Center Yorba Linda, California, United States

View all 32 locations

View Trial Details

Completed

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

NCT01390402

Conditions: Bone Marrow Diseases, Chronic Disease, Chronic Myelogenous Leukemia, +13 more
Locations: University of Texas MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

NCT00538109

Conditions: Bone Marrow Diseases, Chronic Disease, Disease Attributes, +11 more
Locations: Not specified

View Trial Details

Completed

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

NCT00303290

Conditions: Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia, +12 more
Locations: The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

NCT00802841

Conditions: Bone Marrow Diseases, Bronchial Diseases, Bronchiolitis, +22 more
Locations: Novartis Investigative Site Caba, Buenos Aires, Argentina

Novartis Investigative Site Caba, Buenos Aires, Argentina

Novartis Investigative Site La Plata, Buenos Aires, Argentina

Novartis Investigative Site Rio Negro, Viedma, Argentina

View all 56 locations

View Trial Details

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myelogenous, Chronic, BCR-ABL Positive trial results

Related conditions